Prior radiotherapy to the region of the liver that would result in excessive doses to normal tissues due to overlap of radiation therapy fields
Patient must not have had previous irradiation to the head and neck that would result in overlap in radiation fields for the current disease
Prior radiotherapy, including brachytherapy, to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiation therapy to the pelvis that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields except patients who have progressed following stereotactic radiosurgery for 1-3 brain metastases, with at least one new lesion
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields in such a way that curative intent with radiation cannot be met
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the head or neck (except for T1 glottic cancer), that would result in overlap of radiation fields.
Prior receipt of ipsilateral breast or chest wall radiation that would result in significant overlap of radiation therapy fields; prior contralateral radiotherapy for breast cancer is allowed
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the head or neck in overlap of radiation fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation fields
Patients may not have had prior radiotherapy (> 30 Gy) to the area requiring treatment that would result in any overlap of tissue in both fields
Prior radiotherapy that would result in overlap of radiation treatment fields with planned treatment for study cancer.
Prior radiotherapy to the region of the liver that would result in excessive doses to normal tissues due to overlap of radiation therapy fields
Prior radiotherapy to the breast or prior radiation to the region of the ipsilateral breast that would result in overlap of radiation fields
Prior brachytherapy or other radiotherapy that would result in an overlap of radiotherapy fields
Prior radiation therapy to the head or neck resulting in overlap of radiotherapy (RT) fields
Prior radiotherapy for thoracic cancer or other malignancy leading to any overlap of planned radiotherapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy, including brachytherapy, to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in significant overlap of radiation fields
Prior radiotherapy to the pelvis or abdomen that would result in overlap of radiation therapy fields
Prior radiation, including brachytherapy, to the region of the prostate that would result in overlap of radiation therapy (RT) fields
Prior radiation therapy resulting in overlap of radiation therapy (RT) fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields (to include Y90)
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiation therapy to the abdomen that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiotherapy fields
Prior receipt of radiotherapy that would result in overlap of the new and old radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in direct overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields. For example, patients with prior breast radiotherapy treatments would likely be excluded.
Patients who received prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
Prior radiotherapy, including brachytherapy, to the region of the study cancer that would result in overlap of radiation therapy treatment volumes
Prior abdominal radiotherapy that would result in overlap of fields; the treating radiation oncologist should review prior radiation therapy (RT) fields as available
No prior radiotherapy to the ipsilateral breast or prior radiation to the region of the breast that would result in overlap of radiation therapy fields
Prior radiotherapy to the ipsilateral breast or prior radiation to the region of the breast that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
Prior radiotherapy, including brachytherapy, to the region of the prostate that would result in overlap of radiation therapy fields
History of prior malignancy is acceptable, but prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields is not allowed
Prior radiotherapy to the region of the body that would result in overlap of RT fields with the current protocol treatment
Prior neck and/or upper thoracic radiotherapy that would cause an overlap of treatment fields
Prior chemotherapy or radiosensitizers for cancer of the head and neck (except for T1 glottic cancer) that would result in an overlap of radiation fields.
Prior radiation therapy to the head or neck, which would result in overlap of radiation therapy fields
Patient must not have had any prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer:\r\n* Prior radiation therapy for a different cancer or disease process is allowed, provided there will be no overlap of radiation therapy fields between the participant’s prior and current course of radiation therapy, radiotherapy was completed more than four weeks from first fraction of proton therapy administered in this study, and the participant has recovered to grade =< 1 toxicity related to prior radiotherapy
Patients who have previously been treated with brain irradiation to the region that would result in overlap of the radiation fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy that would overlap the anticipated study treatment fields
Prior radiotherapy to the pelvis or abdomen that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the liver that would result in overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior radiotherapy that overlaps with radiation fields
Prior abdominal radiation therapy with fields overlapping the current fields
Prior history of radiation therapy that would lead to overlap with new radiation fields